Filing summary
Entity and period: The supplied filing is Movano Inc.’s unaudited Form 10-Q for the three and nine months ended September 30, 2021, filed November 12, 2021. This differs from the request metadata, which names Corvex, Inc. The summary below reflects the filing text.
Business context and reporting period
Movano is a development-stage health technology company developing RF-based sensors and a proposed wearable intended to measure glucose, blood pressure and heart rate. The company reported no revenue and had not commercialized a product. Its activities and expected spending were principally focused on research and development.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | No revenue reported | No revenue reported |
| Research and development expense | $3.803m | $2.637m | $8.928m | $6.460m |
| General and administrative expense | $1.376m | $0.546m | $4.563m | $1.477m |
| Total operating expenses / operating loss | $5.179m | $3.183m | $13.491m | $7.937m |
| Net loss | $5.173m | $3.341m | $15.468m | $8.105m |
| Net loss per share, basic and diluted | $0.16 | $1.87 | $0.74 | $5.22 |
Loss per share is presented as a loss; the figures above omit the filing’s negative sign for readability. Gross profit and gross margin are not applicable to reported revenue because no revenue was reported.
Cash flow and balance sheet: For the first nine months of 2021, operating cash use was $11.067m, investing cash use was $22.605m, and financing cash provided was $45.095m. Financing was primarily $45.019m of net IPO proceeds. At September 30, cash and cash equivalents were $17.133m and short-term investments were $22.169m, totaling $39.302m. Current assets were $41.014m and current liabilities were $2.790m (working capital of approximately $38.224m). Total assets were $41.571m, total liabilities $3.189m, and stockholders’ equity $38.382m.
No convertible notes or PPP loan remained outstanding at quarter-end: the notes converted into common stock at the March 2021 IPO, and the PPP loan was forgiven. The company reported no material off-balance-sheet arrangements. Its 1.938m outstanding warrants and 4.878m stock options represent potential share dilution.
Material changes versus the prior comparable period
- Nine-month operating expenses increased $5.554m year over year, including a $2.468m increase in R&D and a $3.086m increase in G&A, which management attributed primarily to company growth and increased activity.
- Nine-month net loss increased to $15.468m from $8.105m. The 2021 period included a $1.581m noncash warrant fair-value expense and $0.883m interest expense, partly offset by $0.351m of PPP loan forgiveness income.
- The IPO substantially changed the capital structure: preferred stock and convertible notes converted to common shares, and the company raised net proceeds of approximately $45.0m. Common shares outstanding rose to 32.772m at September 30, 2021 from 6.393m at December 31, 2020.
- Short-term investments were $22.169m at quarter-end, compared with none at December 31, 2020; the company reported only immaterial unrealized losses and no expected credit losses on those securities.
Outlook, commentary, risks and unusual items
- Management expected cash and short-term investments at September 30 to fund projected operating needs for at least 12 months, but said these resources would not be sufficient to complete product development and commercialization. Additional financing may be required; no specific revenue, earnings or product-launch guidance was provided.
- The company expected significant expenses and increasing operating losses for at least the next several years. It may seek equity, debt, collaboration or licensing funding; unavailable or unfavorable financing could force it to delay, reduce or discontinue programs. Equity funding could dilute shareholders, while debt could impose restrictive covenants.
- Management described a working prototype but stated that substantial further R&D was required and that studies had not yet demonstrated product accuracy at levels needed for commercialization. Product feasibility, clinical development, FDA clearance or approval, FCC compliance, manufacturing partners and market acceptance remain material uncertainties.
- Other disclosed risks include competition, dependence on third parties and consultants, intellectual-property disputes, COVID-19-related disruption, personnel retention, and the possibility that the company may not achieve profitability or remain a going concern.
- Disclosure controls and procedures were reported ineffective as of September 30, 2021. Management identified three material weaknesses: inadequate segregation of duties, insufficient IT security and access controls, and insufficient precision in internal-control design. Remediation efforts were underway, but their effectiveness was not assured.
- The company reported no material pending litigation and no subsequent events requiring adjustment or disclosure. The nine-month results included noncash accounting effects from warrant and derivative fair-value changes, debt discount accretion, and the IPO-related conversions.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied text is for Movano Inc., not Corvex, Inc.
- Track cash burn against management’s stated minimum 12-month liquidity estimate, and assess the timing and terms of any additional financing.
- Monitor technical validation, clinical evidence, regulatory pathway and milestones, and progress toward commercialization of the wearable.
- Review remediation of the three material weaknesses and whether disclosure controls and internal financial reporting controls become effective.
- Assess potential dilution from outstanding options, warrants and future financing, alongside the reported 32.772m common shares outstanding at quarter-end.